Suppr超能文献

一系列 SLACK 钾通道黄嘌呤抑制剂的构效关系研究。

Structure-Activity Relationship Studies in a Series of Xanthine Inhibitors of SLACK Potassium Channels.

机构信息

Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.

School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.

出版信息

Molecules. 2024 May 22;29(11):2437. doi: 10.3390/molecules29112437.

Abstract

Gain-of-function mutations in the gene, which encodes the sodium-activated potassium channel known as SLACK, are associated with the rare but devastating developmental and epileptic encephalopathy known as epilepsy of infancy with migrating focal seizures (EIMFS). The design of small molecule inhibitors of SLACK channels represents a potential therapeutic approach to the treatment of EIMFS, other childhood epilepsies, and developmental disorders. Herein, we describe a hit optimization effort centered on a xanthine SLACK inhibitor () discovered via a high-throughput screen. Across three distinct regions of the chemotype, we synthesized 58 new analogs and tested each one in a whole-cell automated patch-clamp assay to develop structure-activity relationships for inhibition of SLACK channels. We further evaluated selected analogs for their selectivity versus a variety of other ion channels and for their activity versus clinically relevant SLACK mutants. Selectivity within the series was quite good, including versus hERG. Analog (VU0948578) was a potent inhibitor of WT, A934T, and G288S SLACK, with IC values between 0.59 and 0.71 µM across these variants. VU0948578 represents a useful in vitro tool compound from a chemotype that is distinct from previously reported small molecule inhibitors of SLACK channels.

摘要

基因中的功能获得性突变,该基因编码称为 SLACK 的钠激活钾通道,与罕见但破坏性的发育性和癫痫性脑病有关,称为婴儿期癫痫伴移行性局灶性发作(EIMFS)。SLACK 通道的小分子抑制剂的设计代表了治疗 EIMFS、其他儿童癫痫和发育障碍的潜在治疗方法。本文描述了一项以黄嘌呤 SLACK 抑制剂 ()为中心的优化工作,该抑制剂是通过高通量筛选发现的。在该化学型的三个不同区域,我们合成了 58 种新的类似物,并在全细胞自动膜片钳测定中对每种类似物进行了测试,以开发抑制 SLACK 通道的构效关系。我们还评估了选定的类似物对各种其他离子通道的选择性以及对临床相关 SLACK 突变体的活性。该系列中的选择性相当好,包括对 hERG 的选择性。类似物 (VU0948578) 是 WT、A934T 和 G288S SLACK 的有效抑制剂,在这些变体中 IC 值在 0.59 至 0.71µM 之间。VU0948578 是一种来自与先前报道的 SLACK 通道小分子抑制剂不同的化学型的有用的体外工具化合物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d2/11173529/fc68611858d7/molecules-29-02437-g001.jpg

相似文献

3
Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies.
Pharm Pat Anal. 2022 Mar;11(2):45-56. doi: 10.4155/ppa-2022-0002. Epub 2022 Apr 4.
4
Structure-activity relationship studies in a new series of 2-amino-N-phenylacetamide inhibitors of Slack potassium channels.
Bioorg Med Chem Lett. 2022 Nov 15;76:129013. doi: 10.1016/j.bmcl.2022.129013. Epub 2022 Sep 29.
6
VU0606170, a Selective Slack Channels Inhibitor, Decreases Calcium Oscillations in Cultured Cortical Neurons.
ACS Chem Neurosci. 2020 Nov 4;11(21):3658-3671. doi: 10.1021/acschemneuro.0c00583. Epub 2020 Oct 14.
7
An Epilepsy-Associated KCNT1 Mutation Enhances Excitability of Human iPSC-Derived Neurons by Increasing Slack K Currents.
J Neurosci. 2019 Sep 11;39(37):7438-7449. doi: 10.1523/JNEUROSCI.1628-18.2019. Epub 2019 Jul 26.
10
KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum.
Brain. 2021 Dec 31;144(12):3635-3650. doi: 10.1093/brain/awab219.

引用本文的文献

本文引用的文献

1
Reduction of is therapeutic in mouse models of and epilepsy.
Front Neurosci. 2023 Oct 13;17:1282201. doi: 10.3389/fnins.2023.1282201. eCollection 2023.
3
The role of istradefylline in the Parkinson's disease armamentarium.
Expert Opin Pharmacother. 2023 May;24(7):863-871. doi: 10.1080/14656566.2023.2201374. Epub 2023 Apr 18.
4
Structure-activity relationship studies in a new series of 2-amino-N-phenylacetamide inhibitors of Slack potassium channels.
Bioorg Med Chem Lett. 2022 Nov 15;76:129013. doi: 10.1016/j.bmcl.2022.129013. Epub 2022 Sep 29.
5
Antisense oligonucleotide therapy for KCNT1 encephalopathy.
JCI Insight. 2022 Dec 8;7(23):e146090. doi: 10.1172/jci.insight.146090.
6
Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies.
Pharm Pat Anal. 2022 Mar;11(2):45-56. doi: 10.4155/ppa-2022-0002. Epub 2022 Apr 4.
7
K1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons.
Neurobiol Dis. 2022 Jun 15;168:105713. doi: 10.1016/j.nbd.2022.105713. Epub 2022 Mar 26.
8
Targeting K1.1 channels in KCNT1-associated epilepsy.
Trends Pharmacol Sci. 2021 Aug;42(8):700-713. doi: 10.1016/j.tips.2021.05.003. Epub 2021 May 29.
9
Discovery of the First Orally Available, Selective K1.1 Inhibitor: and Activity of an Oxadiazole Series.
ACS Med Chem Lett. 2021 Mar 9;12(4):593-602. doi: 10.1021/acsmedchemlett.0c00675. eCollection 2021 Apr 8.
10
VU0606170, a Selective Slack Channels Inhibitor, Decreases Calcium Oscillations in Cultured Cortical Neurons.
ACS Chem Neurosci. 2020 Nov 4;11(21):3658-3671. doi: 10.1021/acschemneuro.0c00583. Epub 2020 Oct 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验